The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination
Abstract
Hyperglycemia is one of the main risk factors for the development of microvascular complications in patients with T2D. However, the main reason of their deaths remain diseases such as myocardial infarction, chronic heart failure, stroke. Although all of the current glucose-lowering drugs are very effective for the correction of hyperglycemia, studies of the last decade proofs that some of them can additionally decrease cardiovascular risk on patients with T2D. So, the influence of empagliflozin, pioglitazone, liraglutide, semaglutide and canagliflozin was characterized as statistically significant positive to the frequency of development of macrovas- cular complications in patients with T2D. However, nowadays a convincing reduction in cardiovascular mortality in patients with T2D, who took empagliflozin and liraglutide was demonstrated only in two clinical studies – EMPA-REG OUTCOME and LEADER. In the following review there are going to be analyzed the significant results of these studies and the peculiarities of the action of these drugs, which, possibly with joint application, have additive effects in reducing cardiovascular risk in patients with T2D.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.